Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Regulator and the Regulated Part II: A Conversation with FDA's Robert Temple and Amgen's Roger Perlmutter

This article was originally published in RPM Report

Executive Summary

FDA’s dean of drug development Robert Temple and Amgen’s head of research and development Roger Perlmutter sat down to discuss opportunities and challenges for biopharmaceutical developers in the current regulatory environment during The RPM Report’s FDA/CMS Summit for Biopharma Executives. This is part two of that discussion.

You may also be interested in...



The Regulator and the Regulated Part I: A Conversation with FDA's Robert Temple and Amgen's Roger Perlmutter

FDA’s dean of drug development Robert Temple and Amgen’s head of research and development Roger Perlmutter sat down for a conversation at the recent FDA/CMS Summit to discuss opportunities and challenges for biopharmaceutical developers in the current regulatory environment.

FDA Neuroscience Director Dunn's Appearance At Tanezumab AdComm Confirms Neurology Office Is Intact

Dunn’s participation at the panel meeting ended speculation that he left the US FDA.

Will Pharma End Up Paying For The Infrastructure Bill?

Or can industry thread the donut hole and prevent government price negotiations from becoming a part of the legislative tsunami?

Topics

Related Companies

UsernamePublicRestriction

Register

PS080803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel